In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


AstraZeneca's Iressa Problem

Executive Summary

In May of this year, two major scientific journals published papers correlating response to Iressa, AstraZeneca's targeted therapy for refractory non-small cell lung cancer, to a series of mutations clustered in a section of the EGFR gene. These widely publicized findings are fueling discussions that are bound to have consequences not only for AstraZeneca, patients and clinicians, but also for many pharmaceutical companies working on targeted therapies.

Related Content

Companion Diagnostics Spark Pharma Deals, But Still Mostly For Cancer
C-Path Proposes NSCLC Initiative for EGFr Drugs and Diagnostics
Molecular Dx as a Hot Spot
AstraZeneca R&D: Balancing Caution & Ambition
The Outlook for Pharmacogenomics Testing in Primary Care
How Experimental Medicine Is Affecting Big Pharma
Forging a Path for Pharmacogenomics at the FDA
Overcoming Skepticism About Cancer Diagnostics
Targeted Therapeutics: Linking EGF Receptor Drugs to Diagnostics
Dako Ponders the Expanding Universe


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts